VICTORIA, July 18, 2018 /CNW/ – To meet global demand, IMMUNOPRECISE ANTIBODIES LTD. (“ImmunoPrecise” or “IPA”) (TSX VENTURE: IPA) (OTC PINK: IPATF) accelerates the launch of its European B-cell facility expansion at its ModiQuest Research division in Oss, the Netherlands.
The new B-cell facility has been launched ahead of schedule, in response to client demand at ImmunoPrecise’s original B-cell facility, which opened last spring in Victoria, British Columbia.
With the current B-cell laboratory in Victoria operating at full capacity, and booked out several months, the expanded offering of the full-service B-cell facility in the EU accelerates the Company’s international growth and ability to meet international demands.
Clients will benefit from ImmunoPrecise’s global scale and combined resources. The expansion initiatives will enable the ImmunoPrecise family of companies to increase its capacity for B-cell services supporting therapeutic antibody development, provide a client-centric focus with worldwide production centers, and help to bring leading antibody discovery services to more pharmaceutical and biotech companies around the world.
“Leveraging IPAs global scale, we are able to massively accelerate the Company’s vision of bringing a single, unified Contract Research Organization (CRO) to pharmaceutical and biotech companies internationally” said Jennifer L. Bath, President and CEO. “ImmunoPrecise’s infrastructure for comprehensive antibody discovery services and global reach enables us to help ensure customer success no matter where they are located in the world.”
ImmunoPrecise’s B-cell facilities use innovative technologies that allow for B-cell screening, sorting and sequencing on a broad range of therapeutically-relevant protein families including challenging multi-membrane spanning proteins. Antibody panels identified directly from B-cells access a greater proportion of the immune repertoire compared to traditional technologies. The Company’s technology greatly increases the speed and depth of antibody discovery.
“ImmunoPrecise’s increased investment in all areas of operations offers more opportunities to clients. As we continue our global roll-out of our innovative and comprehensive antibody discovery platforms, I am reassured by the commitment to scientific excellence and client success that exists at each of our locations across the Netherlands, Canada and the United States”, said Jos Raats, President and CEO of ModiQuest Research. “We are committed to strong and sustained investment in innovation that helps international pharmaceutical and biotech companies meet their scientific and commercial goals.”
“The pharmaceutical industry has increasingly identified its need to out-source antibody discovery to a single source provider who has the expertise and cutting-edge technologies for high throughput discovery with an increased probability of identifying therapeutically relevant antibodies,” said Jennifer Bath. “We anticipate IPA’s global footprint and antibody discovery industry leadership will further the growth and expansion of our platform.”
About ImmunoPrecise Antibodies Ltd.
ImmunoPrecise is a full-service, therapeutic antibody discovery company focused on the next generation of antibody discovery, to deliver the most therapeutically-relevant antibodies, in a shorter period of time, with the highest probability of succeeding to clinical trials.
ImmunoPrecise operates from state-of-the-art laboratory facilities located at the Vancouver Island Technology Park in Victoria, British Columbia, which house its tissue culture and B-cell screening facilities, as well as a Canadian Council for Animal Care (CCAC)-approved animal care unit. ImmunoPrecise operates globally to offer antibody services from target analysis to pre-clinical services, in collaboration with its subsidiary operations at U-Protein Express B.V., in the Life Science Incubator, Utrecht Science Park, Utrecht, and ModiQuest Research, both in the Netherlands.
The services offered to clients include antibody discovery in wild-type and humanized mouse and rat models, as well as rabbit monoclonal antibodies, all against a broad spectrum of antigens. The Company also offers a wide range of species agnostic B-cell screening and sorting services that decrease discovery timelines and greatly enhance the probability of finding a therapeutic antibody of interest. In addition, the Company provides a broad range of supporting services including immunologically-based assays, recombinant protein manufacturing, humanization, optimization, phage display, stable cell line development, and advanced solutions to challenges faced by clients in antibody-related research and development. In addition, cryopreservation services are provided for the storage of valuable biological materials including hybridoma clones, plasmid constructs, and cell lines. The antibodies produced by ImmunoPrecise target a wide variety of therapeutic, diagnostic and research applications.
ImmunoPrecise employs a highly experienced group of R&D scientists. Over the last 25 years, investments in innovative and proprietary technologies and methods have vastly improved the speed and efficiency of monoclonal and polyclonal antibody production.
For further information please contact:
ImmunoPrecise Antibodies Ltd.
Jennifer Bath, CEO
3204-4464 Markham Street.
Victoria, BC V8Z 7X8
For investor relations please contact:
Contact Financial Corp.
1450 – 701 West Georgia St.
Vancouver, BC V7Y 1G5
Forward Looking Information
This news release contains statements that, to the extent they are not recitations of historical fact, may constitute “forward-looking statements” within the meaning of applicable Canadian securities laws. The Company uses words such as “may”, “would”, “could”, “will”, “likely”, “expect”, “believe”, “intend” and similar expressions to identify forward-looking statements. Any such forward-looking statements are based on assumptions and analyses made by ImmunoPrecise in light of its experience and its perception of historical trends, current conditions and expected future developments. However, whether actual results and developments will conform to ImmunoPrecise’s expectations and predictions is subject to any number of risks, assumptions and uncertainties. Many factors could cause ImmunoPrecise’s actual results to differ materially from those expressed or implied by the forward-looking statements contained in this news release. Such factors include, among other things, actual revenues and earnings for IPA being lower than anticipated, and those risks and uncertainties described in ImmunoPrecise’s annual management discussion and analysis for the fiscal year ended April 30, 2017 which can be accessed at www.sedar.com. The “forward-looking statements” contained herein speak only as of the date of this press release and, unless required by applicable law, ImmunoPrecise undertakes no obligation to publicly update or revise such information, whether as a result of new information, future events or otherwise.
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.